Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: HIV Clin Trials. 2016 Jul 28;17(5):204–211. doi: 10.1080/15284336.2016.1212561

Table 2.

Parent microbicide studies enrolling HIV-1 seroconverters to MTN-015

Parent study Study short title Parent study arms Proportion
eligible
participants
enrolled		 Median time
from HIV
seroconversion
to MTN-015
enrollment		 Parent study
reference
HPTN 035 Safety and effectiveness of
BufferGel and PRO2000

  • BufferGel, 0.5%

  • PRO2000 Gel

  • Placebo Gel

  • No Gel

 72% 18 months Abdool Karim, et al., 2011
MTN-003 Tenofovir-based HIV
Preexposure Prophylaxis
(VOICE)

  • Oral tenofovir disoproxil fumarate

  • Oral tenofovir–emtricitabine

  • 1% tenofovir vaginal gel

  • Oral placebo

  • Vaginal gel placebo

 72% 2 months Marrazzo, et al., 2015
MTN-020 Safety and effectiveness of a
dapivirine vaginal ring (ASPIRE)

  • Dapivirine 25 mg vaginal ring

  • Placebo vaginal ring

 71%* NA* Palanee-Phillips, et al., 2015
*

Accrual ongoing; NA not available